drugset / Trial / NCT01495351
Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma
Phase 1
Completed
19 enrolled
AHS Cancer Control Alberta
Abbott · collabTom Baker Cancer Centre · collab
NaSingle-groupOpen-labelTreatment
Summary
The combination of PARP inhibitor (ABT-888) with a proteasome inhibitors (bortezomib) have demonstrated significant anti-myeloma effects in preclinical lab and animal studies. The goal of this phase I trial is to evaluate in patients with relapsed or refractory multiple myeloma the safety, toxicity profile and tolerability of ABT-888 (Veliparib) administered on a schedule including twice daily oral dosing for 14 days followed by 1 week rest in combination with standard dosing of Bortezomib.
Timeline
- Start
- 2011-10
- Primary completion
- 2015-02
- Completion
- 2015-02-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Veliparib | Small molecule | 20 mg | Oral |
| Background | Bortezomib | Small molecule | — | — |